LLY
Eli Lilly and CoLLY is trading at $1179.27, up 0.83% today, with recent headlines questioning whether current upside is priced in despite 48% revenue growth. The stock shows a bullish sentiment on Stocktwits with 13 bullish messages versus 1 bearish, though Reddit mentions have fallen 80% to 1 in the last 24 hours. Google Trends search interest for LLY has seen a slight 2% velocity increase to 34, remaining near its 30-day average of 33.5.
As of 3h ago
0–100 scale across 90-day window
$LXRX Fox News Nails GLP-1 Toxicity: The ACSL5 Solution 🔬💅 Fox News broke the EADV 2026 study: 66% of GLP-1 users report nail disorders, with 39% suffering onycholysis (nails detaching) vs 9% of controls (4x+ risk)! When mass media warns that weight loss causes nails to fall off and hair loss (26% vs 12%), real-world GLP-1 abandonment (>50%) will surge. First principles show why Lexicon’s ACSL5 (LX9851) is the cure: 1. Gut-Local: Acts inside enterocytes—no systemic flooding starving nail matrices or hair follicles. 2. Natural Ileal Brake: Triggers endogenous, meal-timed GLP-1/PYY pulses instead of 24/7 artificial receptor overload. 3. Novo Slide 10 Synergy: -33% combo weight loss lets Novo slash peptide doses in half, eliminating peripheral toxicities while beating monotherapy. This is why Novo committed $1.0B to oral ACSL5. Fox: https://www.foxnews.com/health/people-weight-loss-drugs-report-fingernails-falling-researchers-uncover-surprising-link $NVO $LLY $VTRS $BIB
$LEXX The use-case for DHT in the GLP-1 ecosystem continues to improve. $LLY $NVO $AMGN https://www.pharmexec.com/view/esc-2026-glp1-based-therapies-move-further-mainstream-cardiovascular-care
$LLY sold puts